Fast Five Quiz: Heart Failure With Reduced Ejection Fraction (HFrEF) Treatment Optimization

Alanna Morris, MD


September 09, 2021

In two clinical trials, the addition of the SGLT2 inhibitors dapagliflozin and empagliflozin to standard therapies for patients with HFrEF has resulted in consistent 25%-26% relative risk reduction of the primary endpoint of cardiovascular death or hospitalization for heart failure.

SGLT2 inhibitors have also been shown to slow the progression of renal function decline. In trials of empagliflozin and dapagliflozin, no patients without diabetes developed ketoacidosis, although SGLT2 inhibitors do increase the risk for diabetic ketoacidosis in patients with diabetes and other high-risk conditions.

Learn more about the treatment of HFrEF.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.